Joanna L. Spencer-Segal, MD, PhD

Assistant Professor
University of Michigan
Ann Arbor, MI, United States

Disclosure information not submitted.

Presentation(s):

• ORF09-03 - Discordance between Clinical Guideline Recommendations and Testosterone Prescribing in a Real-World Setting

  Saturday, June 13, 2026
  1:55 PM - 2:00 PM CT

• SUN-141 - Discordance between Clinical Guideline Recommendations and Testosterone Prescribing in a Real-World Setting

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• ORF28-05 - Effect of CAM2029 on Long-Term Biochemical and Symptom Control in Patients with Acromegaly and IGF-I ≤2×ULN According to Prior Injectable Somatostatin Receptor Ligand Dose: Results from ACROINNOVA 2

  Sunday, June 14, 2026
  2:15 PM - 2:30 PM CT

• ORF29-07 - Dexamethasone-Induced Glucocorticoid Resistance in the Brain Is Not Due to Blood-Brain Barrier Exclusion

  Sunday, June 14, 2026
  2:45 PM - 3:00 PM CT

• MON-012 - Safety and Efficacy of A Standardized Osilodrostat Block-and-Replace Protocol with Cortisol Suppression and Methylprednisolone Replacement

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-036 - Long-Term Safety and Efficacy of CAM2029 in Patients with Acromegaly: Results from the ACROINNOVA 2 Open-Label Extension

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-038 - Long-Term CAM2029 Octreotide Depot Maintains Biochemical and Symptom Control in Acromegaly Across A 4-Week Dosing Interval and during Intervals >28 Days: Data from the ACROINNOVA 2 Trial

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT